A new literature review synthesizes evidence connecting intestinal microbiome disruption to sleep disturbances, highlighting specific microbial biomarkers in narcolepsy and opening doors for targeted therapies.

Key takeaways:

• Patients with type 1 narcolepsy exhibit distinct gut microbiota profiles, including an increased abundance of Klebsiella and decreased levels of beneficial genera such as Lactococcus and Blautia
• The review identifies consistent patterns of microbial dysbiosis across multiple conditions, including chronic insomnia, obstructive sleep apnea, and circadian rhythm disorders.
• Microbiota-targeted interventions, such as probiotics, prebiotics, and fecal microbiota transplantation, show potential for improving sleep quality and architecture by modulating neurotransmitters and inflammation.

A literature review published in Brain Medicine illuminates the connections between gut microbiota and sleep regulation, revealing that patients with narcolepsy and other sleep disorders exhibit significant microbial dysbiosis. The research, led by an international team spanning institutions in China and the United States, synthesizes insights into how digestive system bacteria impact sleep-wake cycles.

Specifically addressing narcolepsy type 1 (NT1), the review highlights significant differences in microbial community structure compared to healthy individuals. At the genus level, patients with NT1 show an increased abundance of Klebsiella alongside decreased levels of beneficial genera such as Blautia, Barnesiella, and Lactococcus.

The abundance of Coriobacteriales and Coriobacteriia exhibits a negative correlation with total sleep duration and sleep efficiency, suggesting that reduced levels of these bacteria may contribute to poorer sleep quality. Furthermore, Lactococcus, which plays a potential role in regulating immune responses, negatively correlates with the arousal index. These findings suggest that fragmented sleep in narcolepsy may be tied to an imbalance between immunosuppressive and immunostimulatory microbiotas.

“The gut microbiota is increasingly recognized as a key player in neurological and psychiatric health,” says Lin Lu, professor at Peking University Sixth Hospital, in a release. “Our review demonstrates that disruptions in gut microbiota composition are closely linked to sleep disturbances across multiple disorders.”

Beyond narcolepsy, the review examines microbial alterations across other major sleep disorders. In chronic insomnia, researchers found consistent decreases in beneficial bacterial genera and altered metabolite profiles, particularly involving bile acids and decreased abundances of Ruminococcaceae species. Patients with obstructive sleep apnea (OSA) demonstrate reduced microbial alpha-diversity, with specific bacterial taxa correlating with clinical severity markers like the apnea-hypopnea index and oxygen saturation parameters. Additionally, circadian rhythm disorders, such as those experienced by shift workers, show distinct microbial signatures, including increased abundances of Actinobacteria and Firmicutes linked to heightened intestinal permeability. Recent research in REM sleep behavior disorder has identified decreased Butyricicoccus and Faecalibacterium as potential hallmarks of phenoconversion to Parkinson’s disease, suggesting gut microbiota changes track disease progression.

The researchers identified several biological pathways linking the gut to sleep regulation. Microbial metabolites, such as short-chain fatty acids like butyrate, demonstrate protective effects against sleep disruption. The microbiota also influences the production of neurotransmitters directly involved in sleep. Certain gut bacteria facilitate the production of gamma-aminobutyric acid (GABA), a primary inhibitory neurotransmitter promoting sleep, and serve as major producers of serotonin.

Building on these mechanisms, the research evaluates emerging microbiota-targeted interventions. Probiotics and prebiotics have shown efficacy in clinical trials for improving sleep quality, reducing cortisol levels, and enhancing sleep architecture in patients with chronic insomnia. Fecal microbiota transplantation has also demonstrated efficacy in small clinical studies, leading to improvements in insomnia severity and sleep quality scores.

“While significant progress has been made, important challenges remain,” says Lu in a release. “We need larger, well-controlled clinical trials with standardized methodologies to validate therapeutic approaches and understand individual response variability. Harmonizing techniques across studies, from sample collection and DNA extraction to sleep assessment tools, will enable meaningful cross-study comparisons and accelerate translation to clinical practice.”

More in Gut Microbiome:

ID 264716871@ Luisfilipemoreira | Dreamstime.com